Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib in Treatment-Naive Waldenström Macroglobulinemia
NCT07169331Phase 4Active, not recruiting
- Sponsor
- BeiGene
- Start
- Oct 2025
- Primary completion
- Oct 2028
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 4 trial of zanubrutinib in Waldenström's macroglobulinemia (WM), sponsored by BeiGene. Started Oct 2025; status: active, not recruiting.
02
Drugs
zanubrutinib
03
Conditions
Waldenström's macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT07169331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07169331.